“Phase 2 Study of Cemiplimab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Final Analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s176, https://doi.org/10.25251/skin.7.supp.176.